A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

Sutton, Martin St. John; Rendell, Marc; Dandona, Paresh; Dole, Jo; Murphy, Karen; Patwardhan, Rita; Patel, Jitandrakumar R.; Freed, Martin I.

doi:10.2337/diacare.25.11.2058

Cited by 244 publications

(116 citation statements)

References 23 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…The effect of rosiglitazone therapy on LV mass has been studied in experimental and clinical setting, however revealing controversial results [13-17]. Evidence from experimental studies has shown that administration of thiazolidinediones might be associated with the development of LV hypertrophy [14,37,38].…”

Section: Discussionmentioning

confidence: 99%

“…Thus far, only few studies have evaluated the possible hypertrophic effect of thiazolidinediones in patients [15,17]. St. John Sutton et al [17] studied patients with type 2 diabetes using echocardiography and demonstrated that long-term use of rosiglitazone is not associated with increase in LV mass (or functional impairment).…”

Section: Discussionmentioning

confidence: 99%

“…St. John Sutton et al [17] studied patients with type 2 diabetes using echocardiography and demonstrated that long-term use of rosiglitazone is not associated with increase in LV mass (or functional impairment). Likewise, Ghazzi et al [15] performed an echocardiographic study in patients with type 2 diabetes submitted to troglitazone therapy and could not observe an increase in LV mass either.…”

Section: Discussionmentioning

confidence: 99%

“…The effect of thiazolidinediones on LV mass has been studied previously in experimental and clinical settings, but is however still unclear [13-17]. These clinical studies used 2-dimensional echocardiography to assess LV function and LV mass [15,17].…”

Section: Introductionmentioning

confidence: 99%

“…These clinical studies used 2-dimensional echocardiography to assess LV function and LV mass [15,17]. Cardiovascular magnetic resonance (CMR) however, is a highly reproducible technique allowing for more accurate measurement of LV mass, enabling reduction of sample size [18].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Roes

Dehnavi

Westenberg

et al. 2011

Journal of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

BackgroundTo evaluate the effect of lifestyle intervention in conjunction with rosiglitazone or placebo therapy on left ventricular (LV) mass, using cardiovascular magnetic resonance (CMR) in the metabolic syndrome.MethodsThe present study was a pre-specified substudy of a double-blind randomized controlled trial evaluating the effect of lifestyle intervention in conjunction with rosiglitazone or placebo therapy on carotid artery atherosclerosis in the metabolic syndrome. From this original study population, 10 subjects from the placebo group and 10 from the rosiglitazone group were randomly selected. At baseline and follow-up (52 weeks), clinical and laboratory measurements were assessed and a CMR-examination was performed to evaluate LV mass indexed for body surface area (LV mass-I). Subsequently, the effect of therapy (rosiglitazone vs. placebo) and clinical and laboratory variables on LV mass-I was evaluated.ResultsIn both groups, body mass index, waist circumference, systolic and diastolic blood pressure significantly decreased during follow-up. Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m2 vs. 44.3 ± 5.6 g/m2, p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the rosiglitazone group (54.7 ± 9.9 g/m2 vs. 53.7 ± 9.2 g/m2, p = 0.3). After correction for systolic and diastolic blood pressure and triglyceride, the kind of therapy (rosiglitazone vs. placebo) remained the only significant predictor of LV mass-I reduction.ConclusionsLifestyle intervention resulted in a reduction of LV mass-I in the metabolic syndrome, indicating reverse remodeling. However, rosiglitazone therapy may have inhibited this positive reverse remodeling.Trial registrationCurrent Controlled Trials ISRCTN54951661.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Roes

Dehnavi

Westenberg

et al. 2011

Journal of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

show abstract

Cardiovascular Outcomes in Trials of Oral Diabetes Medications

Selvin¹,

Bolen²,

Yeh³

et al. 2008

Arch Intern Med

278

180

View full text Add to dashboard Cite

Thiazolidinediones as PPAR Agonists

Mudaliar

Henry

2004

International Textbook of Diabetes Mellitus

View full text Add to dashboard Cite

Type 2 diabetes has now reached epidemic proportions across the world and is the cause of substantial morbidity and mortality. It is now well established that intensive control of blood glucose can significantly reduce and ameliorate the microvascular complications of retinopathy, nephropathy, and neuropathy. Unfortunately however, nearly 80% of type 2 diabetic patients die from macrovascular cardiovascular disease. This increased incidence of atherosclerotic disease is intricately associated with insulin resistance, which is a major pathophysiologic abnormality in type 2 diabetes. There is strong evidence that insulin resistance is intricately involved in the development of not only hyperglycemia, but also dyslipidemia, hypertension, hypercoagulation, vasculopathy, and ultimately atherosclerotic cardiovascular disease. This cluster of metabolic abnormalities has been termed the “insulin resistance or metabolic syndrome.” The thiazolidinediones (rosiglitazone and pioglitazone) constitute a new class of oral antidiabetic agents which are “insulin sensitizers” and exert direct effects on the mechanisms of insulin resistance. Through their PPAR‐γ agonist effects, the thiazolidinediones not only improve insulin sensitivity and glycemic control with reduced insulin requirements, but also have potentially favorable effects on other components of the metabolic syndrome. These beneficial effects on lipid metabolism, vascular tone, and endothelial function might directly and indirectly influence cardiovascular risk by favorably altering several proatherogenic metabolic processes. Long‐term studies are needed to determine whether the insulin‐sensitizing effects of the thiazolidinediones have the potential to prevent or delay the development of type 2 diabetes as well as premature atherosclerotic cardiovascular disease, morbidity, and death.

show abstract

A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes

Cited by 244 publications

References 23 publications

Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

Cardiovascular Outcomes in Trials of Oral Diabetes Medications

Thiazolidinediones as PPAR Agonists

Contact Info

Product

Resources

About